“Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s731. doi:10.25251/26swpe94.